Search

Your search keyword '"Dagrada, GianPaolo"' showing total 124 results

Search Constraints

Start Over You searched for: Author "Dagrada, GianPaolo" Remove constraint Author: "Dagrada, GianPaolo" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
124 results on '"Dagrada, GianPaolo"'

Search Results

1. NUT carcinoma of the submandibular gland: A case report.

2. Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft

3. Abstract 6726: Effectiveness of irinotecan plus trabectedin in a desmoplastic small round cell tumor patient-derived xenograft

8. Supplementary Table 1 from Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

9. Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma

10. Supplementary Table 3 from Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

11. Supplementary Table 2 from Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

12. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)

14. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database

16. Epitheliod hemagioendothelioma (EHE) patient-derived model (PDX): Drug activity assessment and validation of novel biomarkers.

18. Trabectedin (T) in desmoplastic small round cell tumor (DSRCT): Report of its effect in 3 relapsed patients (pts) and the comparison of different regimens in a patient-derived xenograft (PDX) model.

19. Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.

20. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network

21. Corrigendum: Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group

22. Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group

23. Gastroblastoma in Adulthood—A Rarity among Rare Cancers—A Case Report and Review of the Literature

24. MOESM1 of The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response

25. Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).

26. Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).

27. Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network.

28. Self-Assembled Nanomicelles as Curcumin Drug Delivery Vehicles: Impact on Solitary Fibrous Tumor Cell Protein Expression and Viability

29. Identification of an actionable mutation of KIT in extraskeletal myxoid chondrosarcoma (EMC).

30. Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor

31. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases

33. Sunitinib (SM) in advanced extraskeletal myxoid chondrosarcoma (EMC): Updated analysis in 11 patients (pts).

34. Doxorubicin plus dacarbazine (DTIC) in advanced solitary fibrous tumor (SFT): An Italian retrospective case series analysis.

35. Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA).

36. Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers

37. Natural history and outcome in a large series of primary dermatofibrosarcoma protuberans (DFSP) treated at a reference institution.

38. Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile.

39. Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma

40. Identification of a gene expression driven progression pathway in myxoid liposarcoma

41. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies

42. Sirolimus in advanced hemangioendothelioma.

43. Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

44. Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma

45. Defining High Risk Myeloma Using Co-Segregating FISH Variables; Results of MRC Myeloma IX

46. Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

48. Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications

49. Multiple Myeloma with IGH-Involving del(14q): Report of 34 Cases.

Catalog

Books, media, physical & digital resources